Press Release

Harnessing Cancer Stem Cell-derived Exosomes


FOR IMMEDIATE RELEASE
2024-01-03

“[...] recent significant advances in understanding [...] CSC-Exos have revealed numerous potential applications for diagnosis and treatment.”


 

BUFFALO, NY- January 3, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, “Therapeutically harnessing cancer stem cell-derived exosomes.”

 

In this editorial, researcher Yong Teng from Emory University discusses cancer stem cell-derived exosomes. Cancer stem cells (CSCs), a small population of cancer cells capable of self-renewal, are thought to serve as a central hub for tumor initiation, growth, metastasis, and recurrence. The potential for using CSCs in the diagnosis and treatment of cancer is gaining recognition. Exosomes are formed when multivesicular endosomes or multivesicular bodies fuse with the outer membrane of the cell, releasing various components such as DNA, RNA, lipids, metabolites, and cytosolic and cell surface proteins. 

 

“Over the past decade, our understanding of the characteristics and function of cancer-associated exosomes has expanded rapidly.”

 

As the major messengers, exosomes present in the tumor microenvironment (TME) play a critical role in maintaining the delicate balance between CSCs and non-CSCs. Given the importance of CSCs, it is reasonable to believe that CSC-derived exosomes (CSC-Exos) are essential for communication between CSCs and other cells in the TME. Accumulating evidence has demonstrated that CSC-Exos contribute significantly to almost all fundamental aspects of cancer, including maintaining a continuous cycle of self-renewal within the TME, exerting control over neighboring or distant cells, enabling cancer cells to evade immune surveillance, and promoting immune tolerance. 

 

“A deeper understanding of the characteristics and functions of CSC-Exos has the potential to lay the foundation for the development of novel clinical tools for diagnosis and prognosis, as well as therapies aimed at preventing tumor progression and recurrence.”

 

Read the full paper: DOI: https://doi.org/10.18632/oncotarget.28542 

 

Correspondence to: Yong Teng

 

Email: yong.teng@emory.edu 

 

Keywords: cancer stem cells, exosomes, the tumor microenvironment, therapeutic target, anticancer strategy

 

 

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open-access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

 

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

X, formerly known as Twitter
Facebook
YouTube
Instagram

LinkedIn

Pinterest

LabTube

SoundCloud

 

Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28542

 

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact media@impactjournals.com.

 

Oncotarget Journal Office

6666 East Quaker Str., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)



Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC